A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib

被引：0
|
作者：
Jewitt, K.
Pilgrim, H. [1 ]
Ward, S. [1 ]
机构：
[1] Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 141卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
105
引用
收藏
页码：38 / 38
页数：1
相关论文
共 50 条
  • [1] A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib.
    Pilgrim, H.
    Jewitt, K.
    Ward, S.
    BLOOD, 2007, 110 (11) : 376B - 376B
  • [2] COST-UTILITY ANALYSIS OF NILOTINIB COMPARED TO IMATINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
    Inocencio, T. J.
    Seetasith, A.
    Newland, A.
    Bose, P.
    Holdford, D.
    VALUE IN HEALTH, 2012, 15 (04) : A223 - A223
  • [3] NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib
    Goulden, Scott
    Sutcliffe, Frances
    Stevens, Andrew
    LANCET ONCOLOGY, 2012, 13 (02): : 127 - 128
  • [4] COST-EFFECTIVENESS ANALYSIS OF NILOTINIB VERSUS DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKEMIA (CML)
    Niu, X.
    Hay, J.
    VALUE IN HEALTH, 2012, 15 (04) : A209 - A210
  • [5] Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand
    Kulpeng, Wantanee
    Sompitak, Sumalai
    Jootar, Saengsuree
    Chansung, Kanchana
    Teerawattananon, Yot
    CLINICAL THERAPEUTICS, 2014, 36 (04) : 534 - 543
  • [6] Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis
    Hiwase, Devendra K.
    Yeung, David T.
    Carne, Lisa
    Ross, David
    Grigg, Andrew
    Hughes, Timothy P.
    BLOOD, 2013, 122 (21)
  • [7] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    Gruber, F. X.
    Ernst, T.
    Porkka, K.
    Engh, R. A.
    Mikkola, I.
    Maier, J.
    Lange, T.
    Hochhaus, A.
    LEUKEMIA, 2012, 26 (01) : 172 - 177
  • [8] NILOTINIB IS ACTIVE IN IMATINIB RESISTANT AND INTOLERANT CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Koren-Michowitz, M. K. M.
    Le Coutre, P.
    Duyster, J.
    Scheid, C.
    Rowe, J. M.
    Goldschmidt, N.
    Ribakovsky, E.
    Nagler, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 222 - 223
  • [9] Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    F X Gruber
    T Ernst
    K Porkka
    R A Engh
    I Mikkola
    J Maier
    T Lange
    A Hochhaus
    Leukemia, 2012, 26 : 172 - 177
  • [10] COST-UTILITY ANALYSIS OF DASATINIB IN PATIENTS WITH IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA (CML) ON CHRONIC (CP), ACCELERATED (AP) AND BLAST (BP) PHASES IN BRAZIL
    Asano, E.
    Nita, M.
    Moellmann-Coelho, A.
    Rached, R.
    Donato, B.
    Rahal, E.
    VALUE IN HEALTH, 2009, 12 (07) : A280 - A281
12345